Shree Ganesh Remedies Ltd Falls to 52-Week Low of Rs.415

Stock Price Movement and Market Context

On 20 Jan 2026, Shree Ganesh Remedies Ltd’s stock recorded an intraday low of Rs.415, down by 2.04% from the previous close. Despite this, the stock managed to touch an intraday high of Rs.434.9, reflecting a 2.66% gain during the session. The day’s overall change was a positive 1.85%, outperforming its sector by 2.25%. However, the closing price at Rs.415 represents the lowest level the stock has seen in the past 52 weeks, a stark contrast to its 52-week high of Rs.950.

The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating sustained downward momentum. This technical positioning suggests that the stock has been under pressure over an extended period.

Meanwhile, the broader market environment has been challenging. The Sensex opened flat but declined by 559.90 points, or 0.72%, closing at 82,647.48. The index remains 4.25% below its 52-week high of 86,159.02 and has experienced a 3.63% loss over the past three weeks. The Sensex is trading below its 50-day moving average, although the 50DMA remains above the 200DMA, signalling some underlying resilience in the market.

Financial Performance and Valuation Metrics

Shree Ganesh Remedies Ltd’s financial results have been under pressure, contributing to the stock’s decline. The company has reported negative results for three consecutive quarters, with Profit Before Tax (PBT) for the latest quarter at Rs.6.02 crores, reflecting a decline of 28.76%. Similarly, Profit After Tax (PAT) for the latest six months stands at Rs.8.41 crores, down by 23.96% compared to previous periods.

The company’s Return on Capital Employed (ROCE) for the half-year is at a low 16.18%, indicating subdued efficiency in generating returns from its capital base. Return on Equity (ROE) is recorded at 13.3%, which, while moderate, aligns with a fair valuation given the stock’s Price to Book Value ratio of 3.5. This valuation places the stock at a discount relative to its peers’ average historical valuations.

Despite the challenges, the company maintains a strong ability to service its debt, with a low Debt to EBITDA ratio of 0.47 times. This suggests that financial leverage is manageable and does not currently pose an immediate risk to the company’s solvency.

Comparative Performance and Market Position

Over the past year, Shree Ganesh Remedies Ltd has underperformed significantly relative to the broader market. The stock has declined by 36.82%, whereas the Sensex has gained 7.20% and the BSE500 index has generated returns of 5.57% over the same period. This divergence highlights the stock’s relative weakness within the Pharmaceuticals & Biotechnology sector and the wider market.

Domestic mutual funds currently hold no stake in the company, which may reflect a cautious stance given the company’s recent financial results and valuation metrics. The absence of institutional backing is notable, especially considering the company’s size and sector presence.

The company’s Mojo Score stands at 26.0, with a Mojo Grade of Strong Sell as of 12 Jan 2026, an upgrade from the previous Sell rating. The Market Cap Grade is 4, indicating a mid-sized market capitalisation within its peer group.

Summary of Key Financial Indicators

To summarise, Shree Ganesh Remedies Ltd’s recent financial and market data reveal several points of note:

• New 52-week low price of Rs.415, down from a high of Rs.950 in the past year.


• Negative quarterly results for three consecutive quarters, with PBT down 28.76% and PAT down 23.96% over recent periods.


• ROCE at 16.18% and ROE at 13.3%, indicating moderate returns on capital and equity.


• Debt to EBITDA ratio of 0.47 times, reflecting a conservative debt position.


• Mojo Grade of Strong Sell with a score of 26.0, reflecting current market sentiment and company fundamentals.


• Underperformance relative to the Sensex and BSE500 indices over the last year.

These factors collectively contribute to the stock’s current valuation and trading levels, as reflected in its recent price movements and technical indicators.

Sector and Market Environment

The Pharmaceuticals & Biotechnology sector has experienced mixed performance recently, with some stocks showing resilience while others face headwinds. Shree Ganesh Remedies Ltd’s performance contrasts with the broader market, which, despite recent volatility, has maintained a positive trajectory over the past year.

The Sensex’s recent three-week decline of 3.63% and its position below the 50-day moving average indicate some caution among investors, but the index remains above its 200-day moving average, suggesting longer-term support.

Within this context, Shree Ganesh Remedies Ltd’s stock has faced more pronounced challenges, as evidenced by its sustained downward trend and valuation metrics.

Conclusion

Shree Ganesh Remedies Ltd’s fall to a 52-week low of Rs.415 reflects a combination of subdued financial results, relative underperformance against market benchmarks, and cautious positioning by institutional investors. The stock’s trading below all major moving averages and its Strong Sell Mojo Grade underscore the current market assessment of the company’s prospects. While the company maintains a manageable debt profile and fair valuation metrics, the recent trend highlights the challenges faced within its sector and the broader market environment.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →